The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Should we use small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)-based therapy for the treatment of large cell neuroendocrine cancer (LCNEC) of the lung?
Nagla Fawzy Abdel Karim
No relevant relationships to disclose
Tariq Namad
No relevant relationships to disclose
Jung Ying
No relevant relationships to disclose
Jiang Wang
No relevant relationships to disclose
Ananta Bhatt
No relevant relationships to disclose
Mohamed Sakkal
No relevant relationships to disclose
John Charles Morris
No relevant relationships to disclose